National Institutes of Health

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

GreenMark Biomedical Inc. is a healthcare company focused on developing minimally invasive technologies utilizing biopolymer nanoparticles derived from natural starch. Founded in 2016 and based in East Lansing, Michigan, with a laboratory in Ann Arbor, the company aims to enhance diagnostic and treatment capabilities in dentistry and oncology. GreenMark offers a mouth rinse product that highlights cavities and early-stage lesions, allowing dentists to accurately assess dental issues using standard dental curing lamps. Additionally, the company is working on medical applications that target anti-cancer drug delivery, facilitating site-specific treatments. Through its innovative approach, GreenMark Biomedical seeks to provide effective health-based solutions that improve patient care.

SonoMotion Inc. is a medical device company focused on developing non-invasive solutions for kidney stone disease. Founded in 2012 and based in San Mateo, California, the company offers innovative products such as Break Wave, which safely fragments large kidney stones, and Stone Clear, which aids in clearing the resulting stone fragments within 15 minutes in an office setting, without the need for general anesthesia or X-ray radiation. SonoMotion is actively involved in advancing its technology, with a stone repositioning solution currently undergoing clinical trials and a second-generation stone-breaking technology in development. The company's mission is to provide effective and cost-efficient treatments for kidney stone patients.

Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

Comprised of Ronald Reagan UCLA Medical Center, UCLA Medical Center, Santa Monica; Resnick Neuropsychiatric Hospital at UCLA, Mattel Children's Hospital UCLA, and the UCLA Medical Group with its wide-reaching system of primary-care and specialty-care offices throughout the region, UCLA Health System is among the most comprehensive and advanced healthcare systems in the world.

IVOS Medical is an innovative medical device company focused on advancing airway management technology.

Vast Therapeutics is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Founded in 2017 and originally known as Novoclem Therapeutics, the company aims to address chronic infections prevalent among the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing innovative therapeutic solutions for individuals facing these challenging health conditions.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Rhealth is a biotechnology company that focuses on delivering advanced health management solutions through an AI-driven platform tailored for hospitals. It aims to enhance the accessibility of analytical and diagnostic information for both physicians and patients. By integrating portable diagnostic and monitoring technologies, Rhealth seeks to transform the way health information is accessed and utilized, ultimately enabling healthcare providers to deliver more timely and effective care.

The University of Louisville is a public research university that offers a wide range of undergraduate and graduate programs across various disciplines. It is particularly known for its contributions to health, engineering, and the humanities. The university actively engages with community partners to enhance its academic and research initiatives, thereby creating a significant impact on education, healthcare, and research industries. Additionally, the University of Louisville School of Dentistry serves as a specialized institute within the university, focusing on dental education and training.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Scripps Health is a private, nonprofit integrated health system based in San Diego, California, dedicated to delivering high-quality medical care to patients and their families. The organization operates top-ranked hospitals and offers a range of services, including preventive care and wellness screenings tailored to various life stages. Additionally, the Scripps Health Foundation supports these efforts through philanthropic initiatives, ensuring the sustainability of quality patient care in the San Diego area.

Elimu Informatics is a developer of cloud-based clinical decision support software designed for healthcare professionals. The company's expertise lies in clinical decision support, semantic normalization, and workflow integration. By focusing on these areas, Elimu Informatics aims to enhance the quality of care, improve patient experiences, and increase usability for healthcare providers. Their solutions allow healthcare professionals to access advanced tools and insights without the burden of additional development costs or lengthy implementation timelines.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in the development of noninvasive electrophysiology devices aimed at monitoring, controlling, and repairing peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions at an earlier stage, track the progression of symptoms over time, and select more precise treatments tailored to individual patients' needs. This innovative approach enhances the ability of healthcare providers to address nerve-related issues effectively.

BMI OrganBank specializes in the development of advanced medical devices and perfusion technology aimed at enhancing the preservation of organs and tissues for transplantation. By collaborating with academic institutions, the company seeks to expand the potential of organ transplantation and improve patient outcomes. Its focus includes innovative solutions that could significantly transform kidney transplantation and other organ preservation methods, ultimately benefiting thousands of patients in need of transplants. The company’s efforts also extend to developing technologies for organ preservation, such as lung ventilators and ex vivo tissue perfusion, which enable healthcare providers to deliver better medical care.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm focuses on creating unique medicines that target the brain, utilizing cutting-edge scientific approaches and novel drug discovery techniques. In addition to its core mission, Sparian is also developing a new analgesic aimed at addressing both acute and chronic pain, further emphasizing its commitment to advancing treatments for CNS-related conditions.

Mount Sinai Health System is an integrated healthcare system based in New York, providing exceptional medical care to local and global communities. Established in 2013 through the merger of Mount Sinai Medical Center and Continuum Health Partners, it encompasses the Icahn School of Medicine and operates seven hospital campuses throughout the New York metropolitan area. The system is recognized for its excellence in research, patient care, and education across various specialties. It features a vast network of over 7,000 primary and specialty care physicians, as well as more than 45 ambulatory practices and 12 minority-owned free-standing ambulatory surgery centers. Mount Sinai is committed to improving healthcare quality and accessibility, focusing on compassionate patient experiences and the development of strong relationships between staff and patients. Additionally, its venture capital arm, Mount Sinai Ventures, invests in healthcare startups, further enhancing its capacity to innovate and respond to the diverse health needs of the populations it serves.

ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for chronic and acute pain management. The company aims to address significant unmet needs in this area, which has traditionally relied on systemic medications. Its flagship product, Neural Ice™, is a drug-free injectable treatment designed to induce reversible inhibition of nerves, offering a non-addictive, locally targeted solution. This therapy provides patients with extended pain relief lasting from thirty to sixty days following a single injection, representing a significant advancement over current pain management methods.

Young Heart Valve is a Polymeric, Hyaluronan-Enhanced Transcatheter Aortic Valves which were developed by engineers with inspiration from nature. The future of heart valve intervention is being altered by Young Heart Valve. Animal tissue is no longer required thanks to Young Heart Valve. Hyaluronan is included into the leaflets of Young Heart Valve's RejuvenateTM TAVR device, forming a biomolecular interpenetrated network that has been shown to be resistant to calcification and thrombosis.

Teal Health is dedicated to improving women's health by providing at-home cervical cancer screenings. The company has developed an FDA-approved device that allows women to perform these essential screenings in the comfort and privacy of their own homes. By simplifying the process, Teal Health aims to encourage timely screenings, which are crucial for early detection and treatment, ultimately striving to eradicate cervical cancer in the United States. The initiative is supported by a group of committed investors who share the vision of transforming women's health experiences.

Pip Care is a healthcare company that specializes in enhancing the surgical journey through a personalized platform designed for health systems. The company collaborates with these systems to streamline the perioperative care process, supporting care teams and patients from pre-surgery preparation to post-operative recovery. Pip Care offers a dedicated app that empowers patients by providing certified health coaches who create individualized care plans, including daily tasks and tailored advice, helping them manage appointments and feel prepared for their surgeries. By focusing on the digitization and automation of perioperative workflows, Pip Care aims to improve surgical outcomes for patients while also enhancing the financial performance of healthcare providers.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

CardieX Limited is a global health technology company specializing in cardiovascular health management. Founded in 1994 and headquartered in Sydney, Australia, the company designs, manufactures, and markets medical devices aimed at measuring patient risk for hypertension, cardiovascular disease, and other vascular disorders. Its product offerings include devices that utilize patented SphygmoCor technology to assess arterial stiffness and central blood pressure waveforms. Additionally, CardieX develops the Arty platform, which provides physiological and health analytics for wearable devices. The company also offers TeleHealth Services, connecting patients with health coaches through digital and mobile tools. CardieX's solutions are provided to hospitals, clinics, research institutions, and pharmaceutical companies globally. The company has strategic partnerships, including a collaboration with Blumio Inc. for developing wearable sensors and a joint development agreement with inHealth for hypertension and cardiovascular programs. CardieX was previously known as AtCor Medical Holdings Limited until its name change in June 2018.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

The University of Michigan, one of the largest universities in the Midwest, offers a diverse array of academic programs that attract over 40,000 undergraduate, graduate, and professional students. Its renowned schools include the Stephen Ross School of Business, the College of Engineering, and prominent law and medical schools. The university also has a vibrant arts scene, highlighted by its Musical Theatre program and the annual Ann Arbor Film Festival, which draws filmmakers globally. In addition to its educational endeavors, the University of Michigan actively manages a significant endowment, investing in alternative assets such as private equity, real estate, and infrastructure to support its mission and enhance its resources. The institution consistently ranks highly in national assessments, reflecting its commitment to academic excellence and innovation.

Southern California University of Health Sciences has been a leader in educating students to be competent and caring integrative healthcare practitioners for over 100 years. SCU has a history of providing the highest levels of patient care and has gained a reputation for excellence in an evidenceinformed curriculum. SCU is the best place to prepare for a successful, significant, and rewarding career.

The Instituto Nacional de Salud Publica is an academic institution whose central commitment to Mexican society is to provide research results to relevant public health problems in order to prevent and control diseases, as well as to train health professionals who help promote healthy living conditions in the community's various groups. population.

Rosalind Franklin University of Medicine and Science, established in 1912, is a North Chicago, Illinois-based institution dedicated to educating future health science leaders. It comprises five schools offering degrees such as Doctor of Medicine, Doctor of Podiatric Medicine, Nurse Anesthesia, Physical Therapy, and Physician's Assistant. The university fosters research and provides opportunities for students to engage in it, both on campus and through partnerships with nearby institutions. It aims to enrich students' lives professionally, mentally, and socially through various organizations and activities. Admission requirements vary by school but generally seek students with a strong scientific background and leadership skills. The university offers financial aid to eligible students who demonstrate need.

Amissa develops mobile and wearable application solutions aimed at alleviating the challenges of Alzheimer's care. The company’s technology empowers caregivers by allowing them to geo-fence and locate loved ones who may wander, remotely monitor their activity and health, and predict behaviors associated with Alzheimer's. In addition to these features, Amissa offers wearable biosensors integrated with a cloud-based data platform that collects biometric data on activity levels, sleep patterns, and physiological changes. This comprehensive approach not only aids caregivers in monitoring patients but also provides valuable insights for researchers seeking to understand disease progression, ultimately enhancing the quality of life for individuals with dementia and related disorders.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.

Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Penderia Technologies is a medical device company focused on innovative orthopedic solutions. It develops implantable, battery-less sensors for monitoring injury and healing progress in real-time, enabling personalized rehabilitation therapies.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. Utilizing its proprietary IMMray platform, which is based on antibody microarray analysis, Immunovia develops and commercializes innovative diagnostic tools. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests, collaborating with medical institutions and research centers worldwide. By concentrating on early detection, Immunovia aims to enhance the treatment and management of pancreatic cancer, thereby improving patient survival rates. The technology developed by Immunovia could also facilitate early detection strategies for other cancers and autoimmune diseases in the future.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials have demonstrated that ANEB-001 is rapidly absorbed and well-tolerated by patients. Additionally, it has been observed to induce weight loss, an effect linked to its action as a central cannabinoid receptor type 1 antagonist. The company aims to address the wide range of symptoms associated with cannabinoid overdose, which can include profound sedation, anxiety, panic, and psychosis with hallucinations.

MaMome is dedicated to advancing women's health, beginning with pregnancy, and extending beyond, by utilizing microbiome coupled with machine learning/AI, we precisely identify expectant mothers at elevated risk of pregnancy complications.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

CUNY SPH promotes and sustains healthier populations in their city and around the world through education, research, and service in public health. They offer essential insights into public health problems and solutions. They believe collaboration leads to innovative and impactful research, programs, and policies.

Preeclampsia Foundation is a nonprofit that focuses on reducing maternal and infant illness and death due to preeclampsia.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

The University of California San Diego (UC San Diego) is a public research university renowned for its diverse undergraduate and graduate programs across multiple disciplines. It emphasizes research, community engagement, and interdisciplinary collaboration, making it a hub for innovation and education. The university houses the School of Medicine, which prepares students for careers in healthcare by equipping them with the necessary knowledge and skills to become dedicated medical professionals. Additionally, UC San Diego fosters a multidisciplinary approach to complex systems through its human-centered design thinking labs, collaborating with various industrial partners in fields such as automation and healthcare. It actively supports student involvement in leadership and offers resources for studying abroad, enhancing the overall educational experience.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Annoviant is a healthcare company focused on the development of innovative medical devices, specifically tissue-based valve and conduit replacement products. These devices are designed to replace or repair structures that are congenitally absent or underdeveloped. Annoviant's offerings are characterized by their regenerative capabilities and resistance to thrombosis, calcification, and infection. By maintaining essential mechanical properties, these devices aim to enhance clinical outcomes for substitute conduit arteries in infants and children, ultimately reducing the need for repeated surgical interventions.

Selsym Biotech is a biotechnology company focused on developing innovative therapies aimed at controlling bleeding in trauma and surgical situations. The company's flagship product, Hemostatic Healing Hydrogels (H3), offers a novel solution to address critical challenges in hemorrhage control, particularly in light of ongoing platelet supply shortages and limitations related to shelf life. By providing effective platelet-mimetic therapies, Selsym Biotech seeks to revolutionize the management of uncontrolled bleeding, enhancing outcomes for patients in emergency and surgical settings.

The Feinstein Institutes is a research services centre.

Cincinnati Children’s Hospital Medical Center is a leading institution dedicated to improving child health, attracting patients and families both regionally and internationally. Recognized for its expertise, the hospital serves as a referral center for complex surgical procedures and treatments for rare pediatric diseases. The center is committed to advancing pediatric medicine by discovering innovative and effective treatment methods, solidifying its reputation as one of the foremost facilities for pediatric care globally.

Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

Perspective Therapeutics is a medical technology and radiopharmaceutical company focused on innovative cancer treatment solutions. The company employs a proprietary technology that uses the alpha-emitting isotope 212Pb combined with specialized targeting peptides to deliver targeted radiation directly to cancer cells. This approach aims to enhance the effectiveness of treatments while minimizing side effects, reflecting the company's commitment to personalized and precise medicine in addressing patients' medical needs.

BetterAge is a digital platform focused on enhancing the health and well-being of older adults. The company aims to empower individuals by providing hyper-personalized assistance that educates users about the risk levels of various diseases. This approach enables older adults to generate actionable insights and guidance, facilitating informed decision-making and connection to necessary resources. By leveraging a network of experts and practitioners in aging services, health, and technology, BetterAge is committed to creating supportive communities that foster active and healthy lifestyles for older individuals. The platform offers unique, expert-driven content tailored specifically for this demographic, promoting a vision where all adults can live well and age gracefully.

AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Amydis is a privately-held pharmaceutical company focused on developing innovative diagnostic solutions for diseases associated with amyloid proteins. The company aims to create a universal, non-invasive diagnostic tool that is faster, more accessible, and affordable than existing tests for conditions with unmet clinical needs. Amydis has developed a platform of novel compounds that fluoresce upon binding to amyloid proteins, facilitating the diagnosis of various diseases. Its primary focus is on the early detection of Alzheimer's disease, but it also explores potential applications for detecting Parkinson’s disease, Creutzfeldt-Jakob disease, Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy. By providing diagnostic capabilities for amyloid-associated diseases, Amydis empowers patients and healthcare professionals to make informed decisions about health risks.

Virtuoso Surgical focuses on developing robotic tools specifically for minimally invasive endoscopic surgery. The company's surgical system features needle-sized robotic arms that allow surgeons to navigate and operate in hard-to-reach areas of the body, addressing limitations posed by traditional endoscopes. By providing dexterous and accurate instruments, Virtuoso Surgical aims to enhance surgical precision and improve patient outcomes while also offering a cost-effective solution for healthcare providers.

The Stark Neurosciences Research Institute is dedicated to improving outcomes for persons suffering from disorders of the nervous system.

Endomimetics is focused on developing advanced bio-nanometric coating technology aimed at enhancing medical care for patients with kidney diseases. The company's innovative stent coating technology is designed to closely mimic human tissue, which helps to minimize the need for additional surgeries and improves the longevity of the devices. By reducing complications associated with the implantation of foreign materials, Endomimetics' technology aims to provide better outcomes for patients, ultimately improving their overall quality of care in the management of kidney-related health issues.

On average, we spend a third of our lives in bed. Our self-positioning bed; the Korus™, combined with our AI-driven software, is designed to provide precise sleep therapies improving lifestyle and medical care that benefits sleep wellness and faster recovery at home.

Rivanna Medical, LLC is a medical technology company based in Charlottesville, Virginia, founded in 2010. The company focuses on developing and commercializing innovative ultrasound-based systems aimed at enhancing the application of spinal and epidural anesthesia through advanced 3D navigation of the lumbar spine. Its flagship product, Accuro, not only facilitates precise anesthesia delivery but also supports various diagnostic imaging needs, including musculoskeletal and abdominal anatomies. Rivanna Medical is committed to improving patient outcomes and lowering healthcare costs while minimizing patient exposure to radiation commonly associated with X-ray-based imaging techniques.

Center for HIV Identification, Prevention, and Treatment Services is a research organisation that conducts HIV research. They offers customer support through email and phone contact.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company focuses on preclinical and toxicology services, utilizing proprietary orthotopic and metastatic tumor models. L2P Research Labs offers a range of advanced technologies, including quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans, as well as focal radiation. These capabilities allow researchers to access a complete suite of research services tailored to their needs, facilitating the advancement of scientific studies and drug development.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in the development of noninvasive electrophysiology devices aimed at monitoring, controlling, and repairing peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions at an earlier stage, track the progression of symptoms over time, and select more precise treatments tailored to individual patients' needs. This innovative approach enhances the ability of healthcare providers to address nerve-related issues effectively.

The University of Kentucky, founded in 1865, is a public, non-profit institution and Kentucky's flagship university. It is dedicated to enhancing lives through high-quality education, research, and service, with a strong emphasis on health care. The university offers a range of graduate and undergraduate programs, particularly in agriculture and mechanical fields. As a land grant institution, it assumes a vital leadership role in promoting diversity, inclusion, economic development, and overall human well-being within the community and beyond.

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to combat herpes simplex virus and its related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutic and prophylactic vaccine candidates that aim to reduce the transmission of the herpes virus and effectively manage symptoms associated with its reactivation. By harnessing rational engineering techniques, Rational Vaccines seeks to revolutionize the treatment, prevention, and diagnosis of herpes infections, ultimately improving the quality of life for those affected by these conditions.

SINTX Technologies, Inc. is a biomaterial company specializing in the research, development, manufacturing, and commercialization of medical implant products made from silicon nitride. Founded in 1996 and headquartered in Salt Lake City, Utah, SINTX offers a range of ceramic-based biomaterial solutions applicable in various medical and industrial fields. The company primarily focuses on producing spinal implant products, marketed under the Valeo brand, which are used in cervical and thoracolumbar surgeries. SINTX operates an ISO 13485 certified manufacturing facility and collaborates with external partners, providing custom manufacturing and development of silicon nitride ceramics for both medical and non-medical applications. Its products are recognized for their biocompatibility, bioactivity, and excellent bone affinity, and have been successfully implanted in patients across the United States, Europe, Brazil, and Taiwan.

Rhaeos is a pioneering company that has developed the first wearable shunt monitor to enhance care for patients with hydrocephalus. Utilizing a novel thermal biosensor, the device allows for noninvasive, real-time monitoring of cerebrospinal fluid flow. This innovative technology, born from collaborative research at Northwestern University involving experts from engineering, medicine, and management, addresses a significant clinical need by providing timely data to improve treatment for chronic medical conditions. Rhaeos's patches are designed to detect fluid flow in various bodily systems, including blood and lymph, facilitating quicker medical responses and advancing the standard of care in neurosurgery and beyond.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing radiotherapies for patients with cancer. The company's lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as a conditioning agent for patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to bone marrow transplantation. Another key candidate, Actimab-A, is in Phase II trials targeting newly diagnosed acute myeloid leukemia in patients aged 60 and older. Additionally, Actinium is developing Actimab-M for penta-refractory multiple myeloma, currently in Phase I trials. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Actinium also collaborates with Astellas Pharma to advance its technology. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in hematology through innovative therapeutic approaches.

Drexel University Dornsife School of Public Health is a public health school that provides education, conducts research, and partners with communities to improve the health of populations.

Omniose is an early-stage biotechnology company focused on developing advanced conjugate vaccines to combat infectious diseases. The company specializes in pneumococcal conjugate vaccines, aiming to offer broader protection against various bacterial strains. Utilizing proprietary bioconjugation technology, Omniose's approach eliminates reliance on synthetic chemistry techniques, allowing for the generation of polysaccharide-protein conjugate-based vaccines targeting multiple pathogens, including respiratory infections caused by Streptococcus pneumoniae. This innovative platform enhances the ability of healthcare professionals to effectively treat patients by providing more comprehensive vaccine options.

Golden Helix specializes in bioinformatics solutions that enhance life science research and translational medicine. With over 20 years of experience, the company offers innovative technologies and analytic services designed to help scientists and healthcare professionals interpret vast amounts of genomic data generated from microarrays and next-generation sequencing. Their cloud-based software efficiently manages, analyzes, and visualizes complex genomic and phenotypic datasets. By streamlining the processes of annotating and filtering variants, Golden Helix empowers biologists and researchers to conduct sophisticated analyses and visualizations independently, reducing the reliance on bioinformatics experts.

University of Minnesota Medical School educates students, provides patient care, and performs biomedical and clinical research. UMN Medical School offers medical, graduate, and undergraduate degree programs, as well as continuing professional development. The Medical School has two campuses based in the Twin Cities and Duluth, Minnesota. The Twin Cities campus is an interdisciplinary research center. The Duluth campus educates 130 first and second-year medical students committed to practicing in rural or American Indian communities.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Boston University Chobanian & Avedisian School of Medicine is a school of medicine focus on treating disadvantaged and underserved populations.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients with urgent unmet medical needs. The company leverages advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, to transform the traditional drug discovery process. By integrating these innovative approaches, Greenstone aims to streamline what is typically a slow and high-failure endeavor into a more rapid and efficient system, ultimately delivering safe and effective therapeutics to patients.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

Daxor Corporation is a medical device and biotechnology firm based in New York, specializing in blood volume measurement. The company developed the BVA-100 Blood Volume Analyzer, which is the first FDA-approved instrument designed to provide rapid and accurate measurement of a patient's true blood volume. This innovative device is utilized in diagnosing and treating various medical conditions, including congestive heart failure, hypertension, and anemia, among others. Daxor also offers additional services such as semen banking, blood storage, and laboratory testing. The company has established a cooperative research agreement with the Uniformed Services University of the Health Sciences to study the efficacy of the BVA-100 in assessing blood volume in traumatic injury contexts. Founded in 1970 and originally known as Idant Corporation, Daxor Corporation has positioned itself at the forefront of medical instrumentation technology.

NeuroGeneces utilizes advanced neuroscience, sleep expertise, and artificial intelligence to deliver brain health assessments aimed at enhancing cognitive longevity. The company has received funding from various reputable sources, including government agencies and private investors. Its flagship product is a sleep headband equipped with machine learning algorithms that analyze EEG data, comparing it against a proprietary normative database to determine an individual's biological brain age. This innovative approach allows healthcare practitioners to objectively evaluate brain function and develop targeted intervention strategies. Additionally, the device monitors sleep patterns, including quantity, quality, and heart rate variability, providing essential support for clinicians focused on wellness and preventative care. By identifying neurodegeneration early, NeuroGeneces aims to empower users to optimize their mental and physical performance.

Nexilico, Inc. is an early-stage biotechnology company based in Albany, California, specializing in precision medicine and microbiome research and development. Founded in 2017, the company focuses on creating advanced predictive computational platforms to enhance drug design and development processes. By pioneering next-generation in silico microbiome technologies, Nexilico aims to deepen the scientific understanding of microbiomes and their impact on health and disease. This knowledge is leveraged to create innovative microbiome-based solutions that improve therapeutic outcomes for various medical treatments.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.

Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Michigan State University, founded in 1855 and located in East Lansing, Michigan, is a comprehensive educational institution offering a wide range of undergraduate, graduate, and research programs across various fields, including business, humanities, science and technology, and public affairs. Its academic structure comprises several colleges, including the Eli Broad College of Business and the Eli Broad Graduate School of Management, among others. In addition to its educational mission, Michigan State University manages an endowment fund with $200 million in assets, employing alternative investment strategies such as buyouts, hedge funds, and venture capital. The endowment aims for a net internal rate of return of 10%, with allocations of up to 11% of total assets dedicated to alternative investments. This fund has been operational since 1988, highlighting the university's commitment to financial stewardship in support of its educational objectives.